Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naratuximab emtansine
- Development stage
- Phase 2
- Lead developer
- Debiopharm
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Naratuximab emtansine is an investigational antibody-drug conjugate (ADC) designed for the treatment of B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL). It consists of a humanized IgG1 monoclonal antibody targeting the cell-surface antigen CD37, covalently linked via a stable thioether-based linker to the cytotoxic maytansinoid DM1. Upon binding to CD37 on malignant B lymphocytes, the ADC is internalized and degraded within the cancer cell, releasing DM1 intracellularly. DM1 disrupts microtubule function, leading to cell cycle arrest and apoptosis. Naratuximab emtansine has shown promising safety and efficacy in phase II trials for relapsed/refractory DLBCL and other B-cell malignancies such as mantle cell lymphoma and follicular lymphoma. The drug benefits from Orphan Drug status and is being developed by Debiopharm[1][3][4][5][7][8].
- Other names
- naratuximab emtansine
02
Targets
CD37TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on naratuximab emtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naratuximab emtansine.